• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群改变对慢性肾脏病进展的影响。

Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.

机构信息

Nephrology Department, IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid, 28040 Madrid, Spain.

Department of Internal Medicine, Koc University School of Medicine, Istanbul 34450, Turkey.

出版信息

Toxins (Basel). 2018 Jul 19;10(7):300. doi: 10.3390/toxins10070300.

DOI:10.3390/toxins10070300
PMID:30029499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6070989/
Abstract

In chronic kidney disease (CKD), accumulation of uremic toxins is associated with an increased risk of CKD progression. Some uremic toxins result from nutrient processing by gut microbiota, yielding precursors of uremic toxins or uremic toxins themselves, such as trimethylamine N-Oxide (TMAO), p-cresyl sulphate, indoxyl sulphate and indole-3 acetic acid. Increased intake of some nutrients may modify the gut microbiota, increasing the number of bacteria that process them to yield uremic toxins. Circulating levels of nutrient-derived uremic toxins are associated to increased risk of CKD progression. This offers the opportunity for therapeutic intervention by either modifying the diet, modifying the microbiota, decreasing uremic toxin production by microbiota, increasing toxin excretion or targeting specific uremic toxins. We now review the link between nutrients, microbiota and uremic toxin with CKD progression. Specific focus will be placed on the generation specific uremic toxins with nephrotoxic potential, the decreased availability of bacteria-derived metabolites with nephroprotective potential, such as vitamin K and butyrate and the cellular and molecular mechanisms linking these toxins and protective factors to kidney diseases. This information provides a conceptual framework that allows the development of novel therapeutic approaches.

摘要

在慢性肾脏病(CKD)中,尿毒症毒素的积累与 CKD 进展的风险增加有关。一些尿毒症毒素是肠道微生物群对营养物质加工的结果,产生尿毒症毒素的前体或尿毒症毒素本身,如三甲胺 N-氧化物(TMAO)、对甲酚硫酸盐、吲哚硫酸和吲哚-3-乙酸。一些营养素摄入的增加可能会改变肠道微生物群,增加处理它们产生尿毒症毒素的细菌数量。来源于营养素的尿毒症毒素的循环水平与 CKD 进展的风险增加有关。这为通过改变饮食、改变微生物群、减少微生物群产生的尿毒症毒素、增加毒素排泄或针对特定尿毒症毒素来进行治疗干预提供了机会。我们现在回顾了营养素、微生物群和尿毒症毒素与 CKD 进展之间的联系。特别关注具有肾毒性的特定尿毒症毒素的产生、具有肾保护潜力的细菌衍生代谢物的可用性降低,如维生素 K 和丁酸盐,以及将这些毒素和保护因素与肾脏疾病联系起来的细胞和分子机制。这些信息提供了一个概念框架,允许开发新的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a2/6070989/d16bf5784df6/toxins-10-00300-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a2/6070989/7e440cba3573/toxins-10-00300-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a2/6070989/d16bf5784df6/toxins-10-00300-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a2/6070989/7e440cba3573/toxins-10-00300-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a2/6070989/d16bf5784df6/toxins-10-00300-g002.jpg

相似文献

1
Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.肠道微生物群改变对慢性肾脏病进展的影响。
Toxins (Basel). 2018 Jul 19;10(7):300. doi: 10.3390/toxins10070300.
2
Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.营养物质转化为毒素:慢性肾脏病中微生物群对营养物质特性的调节作用
Nutrients. 2017 May 12;9(5):489. doi: 10.3390/nu9050489.
3
Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.肠道微生物群衍生的尿毒症毒素对心血管系统矿化的贡献。
Toxins (Basel). 2021 Apr 10;13(4):274. doi: 10.3390/toxins13040274.
4
Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.慢性肾脏病中的微生物组改变:肠道来源尿毒症毒素的全身效应。
Clin Sci (Lond). 2018 Mar 9;132(5):509-522. doi: 10.1042/CS20171107. Print 2018 Mar 15.
5
The Impact of CKD on Uremic Toxins and Gut Microbiota.慢性肾脏病对尿毒症毒素和肠道微生物群的影响。
Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252.
6
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.在慢性肾脏病的不同阶段,肠道微生物群产生蛋白质结合型尿毒症毒素及相关代谢产物的情况并未改变。
Kidney Int. 2020 Jun;97(6):1230-1242. doi: 10.1016/j.kint.2020.01.028. Epub 2020 Feb 17.
7
Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.基于 CE-TOFMS 的代谢组学方法评价肠道微生物群对尿毒症溶质积累的影响。
Kidney Int. 2017 Sep;92(3):634-645. doi: 10.1016/j.kint.2017.02.011. Epub 2017 Apr 8.
8
Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.肠道微生物群产生的尿毒症毒素对骨骼的影响:慢性肾脏病概述
Ther Apher Dial. 2015 Oct;19(5):436-40. doi: 10.1111/1744-9987.12307. Epub 2015 May 5.
9
Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet.慢性肾病患者肠道微生物群产生的氧化三甲胺:关注饮食。
J Ren Nutr. 2015 Nov;25(6):459-65. doi: 10.1053/j.jrn.2015.06.004. Epub 2015 Jul 31.
10
The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.胃肠道和微生物群在尿毒症毒素及慢性肾脏病发展中的作用
Clin Exp Nephrol. 2017 Feb;21(1):7-15. doi: 10.1007/s10157-016-1255-y. Epub 2016 Mar 10.

引用本文的文献

1
Function of Yogurt Fermented with the 11/19-B1 Strain in Improving the Lipid Profile and Intestinal Microbiome in Hemodialysis Patients.11/19-B1菌株发酵酸奶对改善血液透析患者血脂状况和肠道微生物群的作用
Nutrients. 2025 Jun 4;17(11):1931. doi: 10.3390/nu17111931.
2
Bidirectional Interaction Between Chronic Kidney Disease and Infection Drives Inflammation and Immune Dysfunction.慢性肾脏病与感染之间的双向相互作用驱动炎症和免疫功能障碍。
J Immunol Res. 2025 Apr 17;2025:8355738. doi: 10.1155/jimr/8355738. eCollection 2025.
3
Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN.

本文引用的文献

1
Calciphylaxis.钙过敏症
N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292.
2
Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO).多药和毒素外排蛋白 1(MATE1)对三甲基胺 N-氧化物(TMAO)肾脏分泌的贡献。
Sci Rep. 2018 Apr 27;8(1):6659. doi: 10.1038/s41598-018-25139-8.
3
Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota.三甲胺 N-氧化物的代谢反刍和肠道微生物群。
肠道微生物群及其代谢产物:糖尿病肾病的隐藏驱动因素?揭示肠道微生物在糖尿病肾病中的作用。
J Diabetes. 2025 Apr;17(4):e70068. doi: 10.1111/1753-0407.70068.
4
Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases.揭开人类肠道微生物群的奥秘:关于其在不同疾病中作用的综合综述
World J Gastroenterol. 2025 Feb 7;31(5):99913. doi: 10.3748/wjg.v31.i5.99913.
5
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病(MASLD)和代谢功能障碍相关脂肪性肝炎(MASH)对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
6
Indole Lactic Acid in Plasma and Urine: A Potential Biomarker for Chronic Kidney Disease and Inflammatory.血浆和尿液中的吲哚乳酸:一种慢性肾脏病和炎症的潜在生物标志物。
J Inflamm Res. 2024 Jun 26;17:4105-4116. doi: 10.2147/JIR.S458881. eCollection 2024.
7
Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go.糖尿病肾病患者肠道微生物菌群及其代谢产物:任重道远。
Front Cell Infect Microbiol. 2024 May 8;14:1359432. doi: 10.3389/fcimb.2024.1359432. eCollection 2024.
8
Exploring the Causal Effects of Gut Microbiota on Diabetic Nephropathy: A Two-Sample Mendelian Randomization Study.探索肠道微生物群对糖尿病肾病的因果效应:一项两样本孟德尔随机化研究。
Comb Chem High Throughput Screen. 2025;28(6):1026-1038. doi: 10.2174/0113862073311197240425073859.
9
Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.肠道微生物群与慢性肾衰竭之间的因果关系:一项两样本孟德尔随机化研究。
Front Microbiol. 2024 Apr 3;15:1356478. doi: 10.3389/fmicb.2024.1356478. eCollection 2024.
10
Bowel habits were associated with mortality in chronic kidney disease: results from a nationwide prospective cohort study.肠道习惯与慢性肾脏病患者的死亡率相关:一项全国性前瞻性队列研究的结果。
Ren Fail. 2023;45(2):2292150. doi: 10.1080/0886022X.2023.2292150. Epub 2023 Dec 13.
Microbiome. 2018 Apr 20;6(1):73. doi: 10.1186/s40168-018-0461-0.
4
The Role of Gut Microbiota and Diet on Uremic Retention Solutes Production in the Context of Chronic Kidney Disease.肠道微生物群和饮食在慢性肾脏病背景下对尿毒症潴留溶质产生的作用。
Toxins (Basel). 2018 Apr 13;10(4):155. doi: 10.3390/toxins10040155.
5
AGE Content of a Protein Load Is Responsible for Renal Performances: A Pilot Study.蛋白质负荷的年龄含量是影响肾功能的原因:一项初步研究。
Diabetes Care. 2018 Jun;41(6):1292-1294. doi: 10.2337/dc18-0131. Epub 2018 Apr 2.
6
Targeting epigenetic DNA and histone modifications to treat kidney disease.靶向表观遗传 DNA 和组蛋白修饰治疗肾脏疾病。
Nephrol Dial Transplant. 2018 Nov 1;33(11):1875-1886. doi: 10.1093/ndt/gfy009.
7
Albumin downregulates Klotho in tubular cells.白蛋白下调肾小管细胞 Klotho。
Nephrol Dial Transplant. 2018 Oct 1;33(10):1712-1722. doi: 10.1093/ndt/gfx376.
8
Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.口服吸附剂 AST-120 对尿毒症毒素在特定器官蓄积的影响:LC-MS/MS 和 MS 成像技术。
Toxins (Basel). 2017 Dec 28;10(1):19. doi: 10.3390/toxins10010019.
9
Postprandial gut microbiota-driven choline metabolism links dietary cues to adipose tissue dysfunction.餐后肠道微生物群驱动的胆碱代谢将饮食线索与脂肪组织功能障碍联系起来。
Adipocyte. 2018 Jan 2;7(1):49-56. doi: 10.1080/21623945.2017.1398295. Epub 2017 Nov 27.
10
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.抗凝治疗的心房颤动患者的肾脏结局。
J Am Coll Cardiol. 2017 Nov 28;70(21):2621-2632. doi: 10.1016/j.jacc.2017.09.1087.